Serious safety issue forces Novo Nordisk to hit pause on late-stage hemophilia trials

Novo Nordisk
(Novo Nordisk)

Novo Nordisk has halted one midstage and two late-stage tests of its bleeding disease drug concizumab after seeing blood clots in some patients.

The Danish pharma, more known for its diabetes franchise, has been branching out more deeply into hemophilia in the past few years, following a growing market for the bleeding disease. This includes the recent approval for its hemophilia A drug Esperoct and an R&D tie-up with Bluebird Bio for its gene therapy approach to the disease.

Concizumab is a key part of its hemophilia pipeline, but testing of the drug has now been paused, specifically two trials in its phase 3 program (known as explorer7 and 8) and one study in the phase 2 program (explorer5).

Virtual Roundtable

ASCO Explained: Expert predictions and takeaways from the world's biggest cancer meeting

Join FiercePharma for our ASCO pre- and post-show webinar series. We'll bring together a panel of experts to preview what to watch for at ASCO. Cancer experts will highlight closely watched data sets to be unveiled at the virtual meeting--and discuss how they could change prescribing patterns. Following the meeting, we’ll do a post-show wrap up to break down the biggest data that came out over the weekend, as well as the implications they could have for prescribers, patients and drugmakers.

These were testing concizumab as a prophylactic treatment in both hemophilia A and B patients regardless of inhibitor status.

In a brief statement, the biopharma said: “The decision is a result of the occurrence of non-fatal thrombotic events in three patients enrolled in the ongoing phase 3 programme. Novo Nordisk and an independent Data Monitoring Committee are currently assessing the relevance of the events to the continuation of the programme and no conclusions have yet been made.”

It added that no extra patients will be recruited, and further treatment of patients currently enrolled in the trials with concizumab “will cease.”

“While it is disappointing to pause the trials, patient safety is of utmost importance to Novo Nordisk—both for those taking part in our clinical trials and those who use our products on a daily basis,” said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. “Together with relevant authorities, we will now carefully evaluate all available data and decide how to best move forward.”

Suggested Articles

The FDA named more than two dozen coronavirus antibody tests that should be taken off the market weeks after the agency clamped down on tests.

Inovio CEO J. Joseph Kim is undeterred by short sellers and other detractors who doubt his company can shuttle a COVID-19 DNA vaccine to market.

The machine-learning programs scroll through data to detect hard-to-spot patterns. Yet few have been tested against standard procedures.